We are continuing to gain commercial experience with both Crysvita and Mepsevii and will not be providing financial guidance at this time. We have provided launch metrics, including patients on reimbursed therapy, growth in start forms and unique prescribers to help characterize the strength and momentum of our launch. We plan to provide this level of granularity only in the early quarters of launch and we are evaluating the appropriate time to shift specific revenue guidance as we gain experience with the launches in multiple territories.